Search clinical trials for: extended release naltrexone

Total 5795 results

National Institute on Drug Abuse (NIDA)

Not yet recruiting

Trial of Naltrexone/Bupropion for the Treatment of Methamphetamine Use Disorder

Methamphetamine-dependence | Methamphetamine Abuse
University of Texas Southwestern Medical Center
National Institute on Drug Abuse (NIDA)

Recruiting

Extended-Release Naltrexone and Monthly Extended-Release Buprenorphine for Cocaine Use Disorder (CURB-2) (CURB-2)

Cocaine Use Disorder

United States
Spark Biomedical, Inc.
Hazelden Betty Ford Foundation; Gaudenzia, Inc.

Recruiting

Delivering Transcutaneous Auricular Neurostimulation to Improve Relapse Prevention in Opioid Use Disorder (RESTORE)

Opioid-use Disorder | Opioid Withdrawal

United States
University of Pennsylvania
Alkermes, Inc.

Recruiting

Naltrexone in AUD Reward Drinkers

Alcoholism | Alcohol Use Disorder

United States
New York State Psychiatric Institute
National Institute on Drug Abuse (NIDA)

Recruiting

Efficacy of Buprenorphine and XR-Naltrexone Combination for Relapse Prevention in Opioid Use Disorder (COMBO)

Opioid-use Disorder

United States
NYU Langone Health
Harvard Medical School (HMS and HSDM); National Institute on Drug Abuse (NIDA) and other collaborators

Recruiting

Optimizing Retention, Duration and Discontinuation Strategies for Opioid Use Disorder Pharmacotherapy (RDD)

Opioid Use Disorder (OUD)

United States
Friends Research Institute, Inc.

Recruiting

Extended Release Naltrexone Versus Extended Release Buprenorphine With Individuals Leaving Jail

Opioid-use Disorder

United States
Drug Delivery Company, LLC DBA Akyso Pharmaceuticals
National Institute on Drug Abuse (NIDA); Laboratory Corporation of America; Cognitive...

Enrolling by invitation

Study of the BIOPIN 6 Naltrexone Implant in Healthy Adults

Opioid Use Disorder

United States
University of California, Los Angeles

Withdrawn

Relapse Prevention in Stimulant Use Disorder

ADHD | Cognitive Function | Relapse | Stimulant Use

United States
St. Joseph's Healthcare Hamilton
Bausch Health, Canada Inc.

Active, not recruiting

A Trial Evaluating the Effectiveness of Contrave in Patients Who Have Weight Recidivism Following Bariatric Surgery (COR-WR)

Obesity

Canada
St. Joseph's Healthcare Hamilton
Bausch Health, Canada Inc.

Active, not recruiting

Evaluating Contrave for Weight Maintenance in Adults With BMI >= 27 Kg/m2, After 6 Month Behaviour Modification Program. (COR-WM)

Obesity

Canada
University of California, San Francisco
The CARESTAR Foundation

Terminated

Emergency Department Initiated Extended-Release Naltrexone and Case Management for the Treatment of Alcohol Use Disorder

Substance Use | Alcohol Use Disorder | Alcohol Abuse or Dependence

United States
The Cleveland Clinic

Active, not recruiting

EMI-EHP Weight Management and Type 2 Diabetes Pragmatic Trial (EMPOWER-T2D)

Obesity | Type 2 Diabetes

United States
University of Pennsylvania

Completed

Biomarkers of Injectable Extended Release Naltrexone Treatment

Heroin Dependence | Opioid Dependence

United States
Lars Tanum
Oslo University Hospital; Haukeland University Hospital; The Hospital of Vestfold and other collaborators

Completed

Long Acting Naltrexone for Opioid Addiction: Focus on Sustained Abstinence and Recovery (NaltRec)

Opioid-use Disorder

Norway
Ensysce Biosciences
PRA Health Sciences

Completed

Evaluation of Oral PF614 Relative to OxyContin

Healthy Volunteers

United States
NYU Langone Health
National Institute on Alcohol Abuse and Alcoholism (NIAAA)

Completed

Extended-release Naltrexone and Care Management for Alcohol Dependent Frequent Emergency Department Users

Alcohol Dependence | Alcohol Use Disorder

United States
Friends Research Institute, Inc.
National Institute on Drug Abuse (NIDA)

Completed

Extended Release Naltrexone for Opioid-Dependent Youth

Drug Dependence

United States
University of California, Los Angeles
National Institute on Drug Abuse (NIDA); The Emmes Company, LLC

Completed

Cocaine Use Reduction With Buprenorphine (CURB)

Cocaine Dependence

United States
Potomac Health Foundations

Completed

Youth Opioid Recovery Support: A Developmentally-specific Intervention for Home Delivery of Extended Release Naltrexone (YORS)

Opioid-Related Disorders

United States
Boston University
National Institute on Alcohol Abuse and Alcoholism (NIAAA)

Completed

Alcohol Disorder hOsPital Treatment Trial (ADOPT)

Alcohol Dependence | Alcohol Use Disorder | Heavy Drinking

United States
NYU Langone Health
National Institute on Drug Abuse (NIDA); University of California, Los Angeles and other collaborators

Completed

Extended-Release Naltrexone Opioid Treatment at Jail Re-Entry (XOR)

Opioid-Related Disorders | Heroin Dependence

United States
University of Pennsylvania
Patient-Centered Outcomes Research Institute

Completed

Outcomes of Opioid Addicted Prisoners With Extended-Release Injectable Naltrexone (OAPXRNTX)

Opiate Dependence

United States
University of Pennsylvania
National Institute on Drug Abuse (NIDA)

Completed

Opioid Relapse & HIV Risk: 48 Versus 24 Weeks of Injectable Extended Release Naltrexone

Human Immunodeficiency Virus | Opiate Dependence

Russian Federation
University of Wisconsin, Madison
National Institute on Drug Abuse (NIDA)

Completed

Intervention to Expand Opioid Use Disorder Treatment Pharmacotherapy Prescribers

Opioid-use Disorder

United States
Centre for Addiction and Mental Health

Unknown

Vivitrol Treatment for Cannabis Use Disorder

Cannabis Use Disorder

Canada
NYU Langone Health
National Institute on Drug Abuse (NIDA); The Emmes Company, LLC

Completed

Extended-Release Naltrexone vs. Buprenorphine for Opioid Treatment

Opioid Use Disorder

United States
NYU Langone Health

Completed

Extended-Release vs. Oral Naltrexone Alcohol Treatment in Primary Care (X-ON)

Alcohol Dependence

United States
Duke University
Alkermes, Inc.; Laura and John Arnold Foundation; FHR (Fellowship Health Resources... and other collaborators

Completed

Feasibility Study of Extended-release Naltrexone (Vivitrol) in Drug Court Settings (DC)

Opioid-Related Disorders

United States
Yale University
National Institute on Drug Abuse (NIDA); Baystate Medical Center

Completed

Naltrexone for Opioid Dependent Released Human Immunodeficiency Virus Positive (HIV+) Criminal Justice Populations (NewHope)

HIV | Opioid Dependence | AIDS | Drug Dependence

United States
Oregon Health and Science University
National Institute on Drug Abuse (NIDA)

Completed

Comparing Treatments for HIV-Infected Opioid and Alcohol Users in an Integrated Care Effectiveness Study (CHOICES)

Opioid Use Disorder | Alcohol Use Disorder

Canada, United States
Alkermes, Inc.

Completed

Naltrexone for Use in Conjunction With Buprenorphine in Adults With Opioid Use Disorder Prior to First Dose of VIVITROL® (Naltrexone for Extended-Release Injectable Suspension)

Opioid Use Disorder

United States
Oregon Health and Science University
National Institute on Drug Abuse (NIDA)

Completed

Risky Decision Making in Methamphetamine Users: The Role of Opioid Blockade

HIV | Methamphetamine Abuse

United States
Alkermes, Inc.

Completed

ALK21-021: A Safety Study of Medisorb® Naltrexone (VIVITROL®) Administered to Health Care Professionals

Opiate Dependence

United States
University of Oslo
Norwegian Institute of Public Health; Oslo University Hospital; The Research... and other collaborators

Completed

Naltrexone vs Buprenorphine-Naloxone for Opioid Dependence in Norway (NTX-SBX)

Opioid Dependence

Norway
Pfizer

Completed

Healthy Volunteers Study to Estimate the Effects of Food on the Bioavailability of Oxycodone and Naltrexone/6- Β -Naltrexol From a Extended Release Formulation of Oxycodone With Sequestered Naltrexone

Healthy

United States
Rhode Island Hospital

Completed

Distress Tolerance and HIV Prevention With XR-NTX Initiation in Opioid Dependence

Sexually Transmitted Diseases | HIV | Opiate Dependence

United States
Ensysce Biosciences
PRA Health Sciences

Completed

Study of PF614 Compared to OxyContin® in Healthy Volunteers (SAD)

Healthy

United States
Johns Hopkins University
National Institute on Drug Abuse (NIDA)

Completed

The Separate and Combined Effects of Vivitrol and Opiate Abstinence Reinforcement in the Treatment of Opioid Dependence

Opioid Dependence

United States
University of Pennsylvania
National Institute on Drug Abuse (NIDA); Society of Alcoholism and other Addictions

Completed

Extended Release Naltrexone for Treating Amphetamine Dependence in Iceland

Amphetamine Dependence

Iceland
University of Pennsylvania
National Institute on Drug Abuse (NIDA); Alkermes, Inc.

Completed

VIVITROL as a Treatment for Cocaine and Alcohol Dependence

Alcohol Dependence | Cocaine Dependence

United States
New York State Psychiatric Institute
National Institute on Drug Abuse (NIDA)

Completed

Behavioral Naltrexone Therapy for Promoting Adherence to Oral Naltrexone vs Extended Release Injectable Depot Naltrexone (Depot-BNT)

Heroin Dependence | Opiate Dependence

United States
Alkermes, Inc.

Completed

ALK21-010: Long-term Safety of Medisorb® Naltrexone (VIVITROL®) in Alcohol-dependent Adults

Alcoholism
Alkermes, Inc.

Completed

ALK21-018: Effects of Medisorb® Naltrexone (VIVITROL®) on Alcohol Craving in Treatment-seeking, Alcohol-dependent Adults

Alcohol Dependence

United States
Alkermes, Inc.

Completed

ALK21-003: Study of Medisorb® Naltrexone (VIVITROL®) in Alcohol-Dependent Adults

Alcoholism
Yale University
National Institute on Alcohol Abuse and Alcoholism (NIAAA)

Completed

Alcohol Pharmacotherapy for HIV+ Prisoners (INSPIRE)

Alcohol Dependence | Human Immunodeficiency Virus | AIDS | Hazardous Drinking | Problem Drinking

United States
Alkermes, Inc.

Completed

ALK21-013: Efficacy and Safety of Medisorb® Naltrexone (VIVITROL®) in Adults With Opioid Dependence

Opiate Dependence

Russian Federation
Alkermes, Inc.

Completed

ALK21-004: Single-dose Opiate Challenge of Medisorb® Naltrexone (VIVITROL®) in Adults Who Use Opioids

Opiate Dependence
Pfizer

Completed

Safety Study of Oxycodone Hydrochloride and Naltrexone Hydrochloride Extended-Release Capsules in Subjects With Moderate to Severe Chronic Noncancer Pain

Chronic Noncancer Pain

United States
Orexigen Therapeutics, Inc

Completed

Study to Evaluate the Effect of Naltrexone and Bupropion Extended-Release Combination on Cardiac Repolarization in Healthy Participants

Heart Repolarization

United States

Search clinical trials for: extended release naltrexone

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Netherlands

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations